Intended for healthcare professionals

Research News

Zoledronic acid increases bone density but does not reduce fractures in frail elderly people, study finds

BMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h1949 (Published 14 April 2015) Cite this as: BMJ 2015;350:h1949

Re: Zoledronic acid increases bone density but does not reduce fractures in frail elderly people, study finds

As a junior doctor who has worked on an ortho-geriatric job dealing almost exclusively with hip fracture patients, I found this article very interesting. In my experience osteoporotic patients who could not tolerate an oral bisphosphonate were usually given a one off IV Zolendronate. The average age of 40 such patients over the last two years was 91, with many of them being in nursing homes. The study asks the question of whether a costly treatment that often delays discharge and has side effects is worthwhile. This is especially true considering the effectiveness and similar cost of desunomab.

Competing interests: No competing interests

22 April 2015
Robbie A Ley Greaves
Doctor
Iver, Bucks